ABT-898

ABT-898 is a second-generation thrombospondin-1 (TSP-1) mimetic peptide developed by Abbott Laboratories (now AbbVie) as an anti-angiogenic therapy. It is an octapeptide designed to improve upon the pharmacokinetic profile of its predecessor, ABT-510. ABT-898 exerts its therapeutic effect by acting as an agonist for the CD36 receptor (platelet glycoprotein 4) on endothelial cells. This binding triggers a signaling cascade that inhibits endothelial cell migration and induces apoptosis, thereby suppressing tumor neovascularization. While ABT-898 demonstrated efficacy in preclinical models of glioblastoma multiforme and entered Phase 1 clinical trials for advanced solid tumors, its clinical development has since been discontinued. It has also been investigated in veterinary oncology, specifically for the treatment of soft tissue sarcomas in dogs.

Other names

thrombospondin-1 mimetic peptidethrombospondin1 mimetic peptidethrombospondin 1 mimetic peptide